TeleCare North Diabetes

Diabetes Mellitus, Type 2 Clinical Trial

Official title:

TeleCare North Diabetes: A Feasibility Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06134934
• Other study ID #: N-20230026
• Status: Recruiting
• Phase: N/A
• Start date: January 9, 2024
• Est. completion date: March 1, 2025

Study information

• Verified date: January 2024
• Source: Aalborg University Hospital
• Contact: Sisse H Laursen, PhD
• Phone: +4528189779
• Email: sih[@]hst.aau.dk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This feasibility study will evaluate the feasibility of two telemonitoring designs for non-insulin treated T2D patients with an eye to identify the most suitable telemonitoring intervention for a future large-scale randomized trial.

Description:

Background: Maintaining optimal glycaemic control in type 2 diabetes (T2D) is difficult. Telemedicine has potential to support poorly controlled people with T2D in the achievement of glycaemic control if the telemedicine solution includes a telemonitoring component. However, only few telemonitoring solutions for non-insulin treated T2D exist. Therefore, the aim of this feasibility study is to evaluate the feasibility of two telemonitoring intervention designs for non-insulin treated T2D patients with an eye to identify the most suitable telemonitoring intervention for a future large-scale randomized trial. Method: The trial will be conducted as a three-month randomized feasibility study in four municipalities in North Denmark with 15 participants from each municipality. Two different telemonitoring intervention designs will be tested. One intervention will include self-monitoring of blood glucose (SMBG) together with monitoring of sleep and mental health. The second intervention will include an identical setup but with the addition of blood pressure and activity monitoring. Two municipalities will be allocated to one intervention design, whereas the other two municipalities will be allocated to the second intervention design. Qualitative interviews with participants and clinicians will be conducted to gain insight into their experiences with and acceptance of the intervention designs and trial procedures (e.g., blood sampling and questionnaires). In addition, differences in direct intervention costs between the two alternative interventions will be evaluated.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: March 1, 2025
• Est. primary completion date: December 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Women and men = 18 years
• Poorly controlled T2D, i.e. HbA1c > 58 mmol/mol
• Diagnosis of T2D for at least 12 months
• General Practitioner responsible for diabetes treatment
• Residence in Hjørring, Morsø, Jammerbugt, or Rebild municipality
• Ability and willingness to use a smartphone/tablet along with the other devices to be used in the trial
• Signed informed consent
• Ability to understand and read Danish

Exclusion Criteria:

• Pregnancy or breastfeeding
• Insulin treatment
• Prednisolone treatment
• Severe diabetes complications such as severe neuropathy or nephropathy (dialysis treatment)
• Participation in diabetes rehabilitation courses
• Participation in other intervention trials
• Terms that, in the opinion of the sub-investigator or investigator, render the participant unfit to conduct the trial, including lack of understanding of the trial or lack of physical or cognitive ability to participate

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2

Intervention

Other:
• Telemonitoring 1
This telemonitoring intervention design include self-monitoring of blood glucose (SMBG) together with monitoring of sleep, mental health, blood pressure and activity.
• Telemonitoring 2
This telemonitoring intervention design include self-monitoring of blood glucose (SMBG) together with monitoring of sleep and mental health.

Locations

Country	Name	City	State
Denmark	Steno Diabetes Center North Denmark	Aalborg

Sponsors (3)

Lead Sponsor	Collaborator
Aalborg University Hospital	Aalborg University, Steno Diabetes Center Nordjylland

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Experiences with and acceptability of intervention design(s)	Qualitative interviews will be conducted with selected participants and HCPs to gain deeper insight into the participants and HCPs' experiences and acceptability with the two different telemonitoring intervention designs and the trial procedures.	3 months
Secondary	Feasibility of the recruitment assessment 1	Number (whole) of people agreeing to receive participant information letter about the study.	1 month
Secondary	Feasibility of the recruitment assessment 2	Proportion (percentage) of people agreeing to receive participant information letter about the study.	1 month
Secondary	Feasibility of the recruitment assessment 3	Number (whole) of eligible participants who agree to participate.	1 month
Secondary	Feasibility of the recruitment assessment 4	Proportion (percentage) of eligible participants who agree to participate.	1 month
Secondary	Feasibility of the recruitment assessment 5	Potential inequalities regarding recruitment feasibility assessed by comparing those who accepted participation to those who declined with respect to demographic data on age (years), sex (m/f/other), ethnicity (danish/other western/not western), municipality, setting (health care center versus home health care setting), and HbA1c levels (mmol/L).	1 month
Secondary	Retention assessment 1	Number (whole) of participants withdrawing from the trial.	3 months
Secondary	Retention assessment 2	Proportion (percentage) of participants withdrawing from the trial.	3 months
Secondary	Retention assessment 3	Timepoint(s) for withdrawal.	3 months
Secondary	Retention assessment 4	Reasons of discontinuation of the trial.	3 months
Secondary	Retention assessment 5	Potential inequalities regarding retention feasibility assessed by comparing those who retented participation to those who withdrawal with respect to demographic data on age (years), sex (m/f/other), ethnicity (danish/other western/not western), municipality, setting (health care center versus home health care setting), and HbA1c levels (mmol/L).	3 months
Secondary	Adherence to answering the questionnaire: Diabetes-related quality of life: The Problem Areas in Diabetes Questionnaire (PAID-5)	The respons rate for PAID-5 at baseline and at 3 months, respectively.	At baseline (T0) and 3 months (T1)
Secondary	Adherence to answering the questionnaire: Quality of Life: The Short Form 12 Questionnaire (SF-12v2)	The respons rate for SF-12v2 at baseline and at 3 months, respectively.	At baseline (T0) and 3 months (T1)
Secondary	Adherence to answering the questionnaire: Well-being: The World Health Organization Five Well-being Index (WHO-5)	The respons rate for WHO-5 at baseline and at 3 months, respectively.	At baseline (T0) and 3 months (T1)
Secondary	Adherence to answering the questionnaire: The Patient Activation Measure questionnaire (PAM)	The respons rate for PAM at baseline and at 3 months, respectively.	At baseline (T0) and 3 months (T1)
Secondary	Challenges in the blood sampling schedule	Explore through qualitative interviews whether there are any analysis challenges or uncertainties in the clinical workflow with regard to the blood sampling schedule.	At baseline (T0), 3 months (T1), 6 months (T2) and 12 months (T3)
Secondary	Adherence to the blood sampling schedule	Number and proportion of the participants who completes the blood sampling at baseline, 3 months, 6 months, and 12 months, respectively.	At baseline (T0), 3 months (T1), 6 months (T2) and 12 months (T3)
Secondary	Costs	Differences in direct intervention costs between the two alternatives. Resource categories are comprised of equipment and time spent on monitoring, time spent training patients in using the equipment, and potential additional training for community nurses. Resources will be evaluated as prices paid and hourly wages and represented as equivalent annual costs in 2023 prices.	12 months